Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03354728
Recruitment Status : Recruiting
First Posted : November 28, 2017
Last Update Posted : December 25, 2018
Sponsor:
Information provided by (Responsible Party):
City of Hope Medical Center

Brief Summary:
This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who are undergoing donor stem cell transplant. Multi-antigen CMV-modified vaccinia ankara vaccine may help people resist CMV life-threatening complications.

Condition or disease Intervention/treatment Phase
Cytomegalovirus Positive Hematopoietic Cell Transplantation Recipient Biological: Multi-antigen CMV-Modified Vaccinia Ankara Vaccine Other: Laboratory Biomarker Analysis Phase 1 Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To investigate the optimal dose of multi-antigen CMV-modified vaccinia ankara vaccine (Triplex) in CMV-positive pediatric patients receiving human leukocyte antigen (HLA) matched or mismatched hematopoietic cell transplantation (HCT). (Phase I)

II. To evaluate the safety profile of Triplex in this patient population. (Phase I)

III. To determine if Triplex reduces the frequency of CMV events when compared to historical data. (Phase II)

SECONDARY OBJECTIVES:

I. To characterize CMV reactivation and disease by assessing: time to CMV reactivation, duration of viremia, recurrence of viremia, incidence of late CMV viremia/disease (defined as > 100 days and =< 365 days post HCT), use of anti-viral drugs triggered by rising CMV viremia or viremia >= 3750 IU/mL, cumulative number of CMV specific antiviral treatment days.

II. To evaluate the impact of Triplex on transplant related outcomes by assessing the incidence of acute and chronic graft versus host disease (GVHD), relapse, non-relapse mortality (NRM), all-cause mortality, infections.

III. To investigate the impact of Triplex on cellular immunity by investigating: the level, function and kinetics of CMV-specific T-cell immunity, the changes in adaptive natural killer (NK) cell population and highly cytotoxic memory NKG2C+ NK cells, and changes in GVHD biomarkers.

OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

Patients receive multi-antigen CMV-modified vaccinia ankara vaccine intramuscularly (IM) on days 28 and 56 post-HCT.

After completion of study treatment, patients are followed up for up to 365 days.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Phase 1/2 Clinical Study to Evaluate the Optimal Dose and the Protective Effect of CMV-MVA Triplex Vaccine in Pediatric Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant
Actual Study Start Date : August 31, 2018
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : August 2021

Arm Intervention/treatment
Experimental: Treatment (multi-antigen CMV-modified vaccinia ankara vaccine)
Patients receive multi-antigen CMV-modified vaccinia ankara vaccine IM on days 28 and 56 post-HCT.
Biological: Multi-antigen CMV-Modified Vaccinia Ankara Vaccine
Given IM
Other Name: CMV-MVA Triplex Vaccine

Other: Laboratory Biomarker Analysis
Correlative studies




Primary Outcome Measures :
  1. Optimal dose (Phase I) [ Time Frame: Up to 1 year ]
  2. Incidence of adverse events (Phase I) [ Time Frame: Up to 1 year ]
  3. Cytomegalovirus (CMV) events (reactivation >= 1250 IU/mL), or viremia treated by anti-viral therapy, or detection of CMV by histology) (Phase II) [ Time Frame: Prior to day 100 post-hematopoietic cell transplantation (HCT) or viremia treated by anti-viral therapy, or detection of CMV by histology ]
    Will be assessed with exact 90% confidence bounds.

  4. Non-relapse mortality [ Time Frame: At 100 days post-HCT ]
    Will be compared to historical controls at the final analysis, and a 90% lower confidence bound on the difference in 12-month event free survival will be produced.

  5. Severe (grade 3-4) acute graft versus host disease (aGVHD) [ Time Frame: Within 2 weeks from each vaccination ]
  6. Incidence of grade 3-4 adverse events [ Time Frame: Within 2 weeks from each vaccination ]
    Will be graded per Common Terminology Criteria for Adverse Events version 4.0.


Secondary Outcome Measures :
  1. Time-to viremia [ Time Frame: Number of days from transplant to the date of > 1250 IU/mL, assessed up to 1 year ]
  2. Duration of viremia [ Time Frame: Up to 1 year ]
  3. Incidence of late CMV viremia [ Time Frame: > 100 and =< 365 days post-HCT ]
  4. Use of antiviral drugs (triggered by rising CMV viremia or viremia =>3,750 IU/ml) [ Time Frame: Up to 1 year, rising CMV viremia or viremia =>3,705 ]
  5. Cumulative number of CMV specific antiviral treatment days [ Time Frame: Up to 1 year ]
  6. Time to engraftment [ Time Frame: Up to 1 year ]
  7. Incidence of acute graft versus host disease (aGVHD) [ Time Frame: Up to 1 year ]
  8. Chronic GVHD (cGVHD) [ Time Frame: Up to 1 year ]
  9. Relapse defined by bone marrow and/or imaging studies [ Time Frame: Up to 1 year ]
  10. Non-relapse mortality [ Time Frame: Up to 1 year ]
  11. All-cause mortality [ Time Frame: Up to 1 year ]
  12. Infections [ Time Frame: Up to 1 year ]
  13. Levels of CMV-specific T cell immunity [ Time Frame: Up to 1 year post-HCT ]
    Will be combined with immunophenotyping and functional studies. The data analysis for estimating the effect of vaccination on cellular immunity will necessarily be more exploratory in nature. The longitudinal CMV-specific cellular assay data will be modeled on a logarithmic scale, using a generalized estimating equation approach to accommodate the stochastic dependence through time. This produces an estimated multiplicative effect of vaccination, qualified by a valid estimate of variability.

  14. Kinetics of CMV-specific T cell immunity [ Time Frame: Up to 1 year post-HCT ]
    The data analysis for estimating the effect of vaccination on cellular immunity will necessarily be more exploratory in nature. The longitudinal CMV-specific cellular assay data will be modeled on a logarithmic scale, using a generalized estimating equation approach to accommodate the stochastic dependence through time. This produces an estimated multiplicative effect of vaccination, qualified by a valid estimate of variability.

  15. NK phenotype [ Time Frame: Up to 1 year post-HCT ]
    The data analysis for estimating the effect of vaccination on cellular immunity will necessarily be more exploratory in nature. The longitudinal CMV-specific cellular assay data will be modeled on a logarithmic scale.

  16. NK function (cytotoxicity and cytokine production) [ Time Frame: Up to 1 year post-HCT ]
    The data analysis for estimating the effect of vaccination on cellular immunity will necessarily be more exploratory in nature. The longitudinal CMV-specific cellular assay data will be modeled on a logarithmic scale, using a generalized estimating equation approach to accommodate the stochastic dependence through time. This produces an estimated multiplicative effect of vaccination, qualified by a valid estimate of variability.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All subjects (or their guardians) must have the ability to understand and the willingness to sign a written informed consent; age appropriate assent will be obtained per institutional guidelines; to allow non-English patients to participate in this study, bilingual health services will be provided in the appropriate language when feasible
  • Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT
  • Planned allogenic (allo)-HCT, with 9/10 or 10/10 (A, B, C, DRB1, DQB1) high/intermediate resolution HLA donor allele matching and with no T-cell depletion of graft
  • Planned related HCT with molecular 3/6 HLA donor allele matching (haploidentical) (for phase I only)
  • CMV seropositive at the time of HCT
  • Conditioning and immunosuppressive regimens according to institutional guidelines are permitted
  • Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
  • Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and, if hepatitis B virus (HBV) core seropositive, absence of HBV deoxyribonucleic acid (DNA) within 2 months of registration
  • Agreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for up to 90 days post-HCT; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately

Exclusion Criteria:

  • TRANSPLANT RELATED CRITERIA: Patients undergoing cord blood transplant (CB-HCT)
  • Any prior investigational CMV vaccine
  • Anti-CMV therapy in the last 6 months
  • Live attenuated vaccines
  • Medically indicated subunit (Engerix-B for HBV; Gardasil for human papillomavirus [HPV]) or killed vaccine (e.g. influenza, pneumococcal)
  • Allergy treatment with antigens injections
  • Alemtuzumab, cyclophosphamide, ATG or any equivalent in vivo T-cell depleting agent; Note: Pre transplant ATG is permitted
  • Antiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)/valine (VAL), FOS, Cidofovir, CMX-001, maribavir; acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV)
  • Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment; intravenous immunoglobulin therapy (IVIG) is allowed
  • Other investigational product-concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited
  • Other medications that might interfere with the evaluation of the investigational product
  • Patients with congenital immune deficiency
  • Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years are not eligible, the exception to this is patients with aplastic anemia, who are eligible
  • Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., social/psychological issues, etc
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issue related to feasibility/logistics)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03354728


Contacts
Layout table for location contacts
Contact: Weili Sun, MD, PhD 626 256-4673 weilisun@coh.org

Locations
Layout table for location information
United States, California
City of Hope Medical Center Recruiting
Duarte, California, United States, 91010
Contact: Weili Sun, MD, PhD    626-256-4673      
Principal Investigator: Weili Sun, MD, PhD         
Children's Hospital Los Angeles Not yet recruiting
Los Angeles, California, United States, 90027
Contact: Michael Pulsipher, MD    323-361-2546      
Principal Investigator: Michael Pulsipher, MD         
Sponsors and Collaborators
City of Hope Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Weili Sun, MD, PhD City of Hope Medical Center

Layout table for additonal information
Responsible Party: City of Hope Medical Center
ClinicalTrials.gov Identifier: NCT03354728     History of Changes
Other Study ID Numbers: 17236
NCI-2017-02046 ( Registry Identifier: NCI CTRP )
First Posted: November 28, 2017    Key Record Dates
Last Update Posted: December 25, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Vaccines
Immunologic Factors
Physiological Effects of Drugs